Voyager Therapeutics (VYGR) Misses Q3 EPS by 1c

Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.59), $0.01 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $4.61 million versus the consensus estimate of $2.91 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs